Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Bressler

Showing results (81-90 of 191) with videos related to

Pageof 20
Sort By:
Gastroenterology Research and Practice|June 12, 2015
Site-Specific Immunomodulator: A Novel Treatment for Crohn's DiseaseBrian Bressler, Kevin P Bethel, Ralf Kleef, et al.
Journal of Clinical Gastroenterology|August 5, 2024
Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn's Disease: Results From the EVOLVE StudyAndres J Yarur, Brian Bressler, Neil R Brett, et al.
Canadian Journal of Gastroenterology & Hepatology|March 9, 2017
Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic AgentsYvonne Tse, David Armstrong, Christopher N Andrews, et al.
Journal of Crohn'S & Colitis|December 5, 2019
Enteroids Derived From Inflammatory Bowel Disease Patients Display Dysregulated Endoplasmic Reticulum Stress Pathways, Leading to Differential Inflammatory Responses and Dendritic Cell MaturationWilliam D Rees, Martin Stahl, Kevan Jacobson, et al.
Scandinavian Journal of Gastroenterology|August 26, 2010
Immunogenicity of Mycobacterium avium subsp. paratuberculosis proteins in Crohn's disease patientsHoracio Bach, Hin Hin Ko, Eran A Raizman, et al.
Clinical and Experimental Gastroenterology|February 1, 2024
Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn's Disease: Feasibility in the VERSIFY Phase 3 Clinical TrialJordi Rimola, Jean-Frédéric Colombel, Brian Bressler, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|October 10, 2013
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologicsShane M Devlin, Brian Bressler, Charles N Bernstein, et al.
Gastrointestinal Endoscopy|August 20, 2021
Clinician perspectives on the use of artificial intelligence in inflammatory bowel diseaseGaurav B Nigam, Rajan N Patel, Brian Bressler, et al.
Inflammatory Bowel Diseases|December 12, 2018
IBDoc Canadian User Performance EvaluationAlice C Moore, Vivian W Huang, Raymond Bourdages, et al.
Journal of Clinical Gastroenterology|February 23, 2026
Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion Chart Review StudyMarc Ferrante, Britt Christensen, Brian Bressler, et al.
Pageof 20

Showing results (81-90 of 191) with videos related to

Sort By:
Pageof 20
Gastroenterology Research and Practice|June 12, 2015
Site-Specific Immunomodulator: A Novel Treatment for Crohn's DiseaseBrian Bressler, Kevin P Bethel, Ralf Kleef, et al.
Journal of Clinical Gastroenterology|August 5, 2024
Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn's Disease: Results From the EVOLVE StudyAndres J Yarur, Brian Bressler, Neil R Brett, et al.
Canadian Journal of Gastroenterology & Hepatology|March 9, 2017
Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic AgentsYvonne Tse, David Armstrong, Christopher N Andrews, et al.
Journal of Crohn'S & Colitis|December 5, 2019
Enteroids Derived From Inflammatory Bowel Disease Patients Display Dysregulated Endoplasmic Reticulum Stress Pathways, Leading to Differential Inflammatory Responses and Dendritic Cell MaturationWilliam D Rees, Martin Stahl, Kevan Jacobson, et al.
Scandinavian Journal of Gastroenterology|August 26, 2010
Immunogenicity of Mycobacterium avium subsp. paratuberculosis proteins in Crohn's disease patientsHoracio Bach, Hin Hin Ko, Eran A Raizman, et al.
Clinical and Experimental Gastroenterology|February 1, 2024
Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn's Disease: Feasibility in the VERSIFY Phase 3 Clinical TrialJordi Rimola, Jean-Frédéric Colombel, Brian Bressler, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|October 10, 2013
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologicsShane M Devlin, Brian Bressler, Charles N Bernstein, et al.
Gastrointestinal Endoscopy|August 20, 2021
Clinician perspectives on the use of artificial intelligence in inflammatory bowel diseaseGaurav B Nigam, Rajan N Patel, Brian Bressler, et al.
Inflammatory Bowel Diseases|December 12, 2018
IBDoc Canadian User Performance EvaluationAlice C Moore, Vivian W Huang, Raymond Bourdages, et al.
Journal of Clinical Gastroenterology|February 23, 2026
Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion Chart Review StudyMarc Ferrante, Britt Christensen, Brian Bressler, et al.
Pageof 20